Isomorphic Labs, an Alphabet company, says it has raised $5 billion in Series C funding, with Greenoaks and Sequoia Capital co-leading the round announced on November 17, 2026. It’s an enormous bankroll for an enormous ambition: designing new medicines with AI. SourceSource
Andreessen Horowitz joined the round alongside other new investors, while Alphabet continued investing, according to the company. Isomorphic says all its existing investors also participated: Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund. Source
The raise comes just six months after Isomorphic announced its previous fundraising effort, Bloomberg reports. The fundraising calendar, at least, isn’t hanging around. Source
Isomorphic says it is scaling IsoDDE, its proprietary drug-design engine, and its pipeline of AI-designed therapeutic candidates, or potential medicines. The announcement page does not specify how the $5 billion will be divided between those activities. Source
Demis Hassabis wrote that the funding would “accelerate our mission to Solve All Disease.” He also said the company was making rapid progress using AI to radically cut the time and cost of finding new medicines. That is quite a job description, even with $5 billion behind it. Source
The short announcement page provides no clinical results or quantified evidence of time or cost savings. Source
Comments